Subscriber Authentication Point
lvrea
Home All issues Volume 24 / No 3 (Mai 2015) Réanimation, 24 3 (2015) 270-277 References
Free Access
Issue
Réanimation
Volume 24, Number 3, Mai 2015
Infectieux
Page(s) 270 - 277
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-015-1059-1
Published online 01 April 2015
  • Rottier WC, Amerlaan H, Bonten M (2012) Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 67:1311–1320 [CrossRef] [PubMed] [Google Scholar]
  • Oteo J, Perez-Vazquez M, Campos J (2010) Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 23:320–326 [CrossRef] [PubMed] [Google Scholar]
  • Collins VL, Marchaim D, Pogue JM, et al (2012) Efficacy of ertapenem for treatment of bloodstream infections caused by extendedspectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 56:2173–2177 [CrossRef] [PubMed] [Google Scholar]
  • Hombach M, Mouttet B, Bloemberg GV (2013) Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of EBSL-and AmpC β-lactamases producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother 68:2092–2098 [CrossRef] [PubMed] [Google Scholar]
  • Betriu C, Salso S, Sánchez A, et al (2006) Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents 28:1–5 [CrossRef] [PubMed] [Google Scholar]
  • Wu N, Chen B, Tian S, et al (2014) The inoculum effect of antibiotics against CTX-M-extended-spectrum ß-lactamase-producing Escherichia coli. Ann Clin Microbiol Antimicrob 13:45 [PubMed] [Google Scholar]
  • Afssaps (2011) Dix ans d’évolution des consommations d’antibiotiques en France. http://wwwafssapsfr/var/afssaps_site/storage/original/application/263354f238b8f7061cdb52319655ca07 [Google Scholar]
  • Nordmann P, Naas T, Poirel L (2011) Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798 [CrossRef] [PubMed] [Google Scholar]
  • Nordmann P (2014) Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 44:51–56 [CrossRef] [PubMed] [Google Scholar]
  • Brun-Buisson C, Legrand P, Philippon A, et al (1987) Transferable enzymatic resistance to third-genera-tion cephalosporins during nosocomial outbreak of multiresis-tant Klebsiella pneumoniae. Lancet 2:302–306 [CrossRef] [PubMed] [Google Scholar]
  • Sader HS, Hsiung A, Fritsche TR, et al (2007) Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 57:341–344 [CrossRef] [Google Scholar]
  • Labombardi VJ, Rojtman A, Tran K (2006) Use of cefepime for the treatment of infections caused by extended spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 56:313–315 [CrossRef] [Google Scholar]
  • Zanetti G, Bally F, Greub G, et al (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442–3447 [CrossRef] [PubMed] [Google Scholar]
  • Kahlmeter G (2008) Breakpoints for intravenously used cephalosporins in Enterobacteriaceae — EUCAST and CLSI breakpoints. Clin Microbiol Infect 14:S169–S174 [CrossRef] [Google Scholar]
  • Kotapati S, Kuti JL, Nightingale CH, et al (2005) Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 51:211–217 [CrossRef] [PubMed] [Google Scholar]
  • Lee NY, Lee CC, Huang WH, et al (2013) Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum β-lactamase–producing Enterobacteriaceae: MIC Matters. Clin Infect Dis 56:488–495 [CrossRef] [PubMed] [Google Scholar]
  • Andes D, Craig WA (2005) Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 11:10–17 [CrossRef] [PubMed] [Google Scholar]
  • Martínez J, Cobos-Trigueros A, Soriano A, et al (2010) Influence of empiric therapy with a β-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms. Antimicrob Agents Chemother 54:3590–3596 [CrossRef] [PubMed] [Google Scholar]
  • Paterson DL, Ko WC, Von Gottberg A, et al (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206–2212 [CrossRef] [PubMed] [Google Scholar]
  • Kang CI, Kim SH, Park WB, et al (2004) Bloodstream infections due to extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581 [CrossRef] [PubMed] [Google Scholar]
  • Falagas ME, Tansarli GS, Rafailidis PI (2012) Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother 56:4214–4222 [CrossRef] [PubMed] [Google Scholar]
  • Goethaert K, Van Looveren M, Lammens C, et al (2006) High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 12:56–62 [CrossRef] [PubMed] [Google Scholar]
  • Ambrose PG, Bhavnani SM, Jones RN (2003) Pharmacokinetics pharmacodynamics of cefepime and piperacillin/tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 47:1643–1646 [CrossRef] [PubMed] [Google Scholar]
  • Canoui E, Tankovic J, Bige N, et al (2014) Which proportion of extended-spectrum β-lactamase producing strains could be treated by non-carbapenem beta-lactams? Med Mal Inf 44:232–237 [CrossRef] [Google Scholar]
  • Comité de l’antibiogramme de la Société française de microbiologie. Argumentaire pour les recommandations faites en 2011 à propos des C3G et de l’aztréonam vis-à-vis des entérobactéries. http://www.infectiologie.com/site/medias/Recos/2011-Argu-Reco-CaSFM.pdf [Google Scholar]
  • Rodriguez-Bano J, Navarro M, Retamar P, et al (2012) β-Lactam/ β-Lactam inhibitor combinations for the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli: a post-hoc analysis of prospective cohorts. Clin Infect Dis 54:167–174 [CrossRef] [PubMed] [Google Scholar]
  • Retamar P, Lopez-Cerero L, Muniain MA, et al (2013) Impact of the MIC of piperacillin/tazobactam on the outcome of patients with bacteriema due to extended spectrum beta lactamase producing Escherichia coli. Antimicrob Agents Chemother 57:3402–3404 [CrossRef] [PubMed] [Google Scholar]
  • Pal RB, Pal P, Jain S, et al (2008) In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime + clavulanic acid among β-lactamase positive clinical isolates of gram-positive and Gram-negative pathogens. J Indian Med Assoc 106:545–548 [PubMed] [Google Scholar]
  • Vardakas KZ, Tansarli GS, Rafailidis PI, et al (2012) Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67:2793–2803 [CrossRef] [PubMed] [Google Scholar]
  • Gauzit R, Craig A, Brun-Buisson C, et al (2010) Recommandations de bon usage des carbapénèmes. J Anti Inf 12:183–189 [Google Scholar]
  • Emery CL, Weymouth LA (1997) Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 35:2061–2067 [PubMed] [Google Scholar]
  • Ho PL, Chan WM, Tsang KW, et al (2002) Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 34:567–573 [CrossRef] [PubMed] [Google Scholar]
  • Suankratay C, Jutivorakool K, Jirajariyavej S (2008) A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum β-lactamase-producing bacteria. J Med Assoc Thai 91:1172–1181 [PubMed] [Google Scholar]
  • Asakura T, Ikeda M, Nakamura A, et al (2014) Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum β-lactamase-producing Enterobacteriaceae. Int J Infect Dis 29:91–95 [CrossRef] [PubMed] [Google Scholar]
  • Lepeule R, Ruppe E, Le P, Massias L, et al (2012) Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. Antimicrob Agents Chemother 56:1376–1381 [CrossRef] [PubMed] [Google Scholar]
  • Bin C, Hui W, Renyuan Z, et al (2006) Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56:351–357 [CrossRef] [Google Scholar]
  • Dudley MN, Ambrose PG, Bhavnani SM, et al (2013) Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: cephalosporins and aztreonam. Clin Infect Dis 56:1301–1309 [CrossRef] [PubMed] [Google Scholar]
  • Karim A, Poirel L, Nagarajan S, et al (2001) Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 201:237–241 [PubMed] [Google Scholar]
  • Jacoby GA, Carreras I (1990) Activities of βlactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 34:858–862 [CrossRef] [PubMed] [Google Scholar]
  • Pangon B, Bizet C, Bure A, et al (1989) In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis 159:1005–1006 [CrossRef] [PubMed] [Google Scholar]
  • Balakrishnan I, Awad-El-Kariem FM, Aali A, et al (2011) Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66:2628–2631 [CrossRef] [PubMed] [Google Scholar]
  • Zhanel GG, Lawson CD, Adam H, et al (2013) Ceftazidime–avibactam: a novel cepha-losporin/βlactamase inhibitor combination. Drugs 73:159–177 [CrossRef] [PubMed] [Google Scholar]
  • Flamm R, Sader H, Farrell D, et al (2014) Ceftazidime–avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80:233–238 [CrossRef] [Google Scholar]
  • Bhalodi AA, Crandon JL, Williams G, et al (2014) Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in at high model. Int J Antimicrob Agents 44:508–513 [CrossRef] [PubMed] [Google Scholar]
  • Yoshizumi A, Ishii Y, Aoki K, et al (2015) In vitro susceptibility of characterized β-lactamase-producing Gram negative bacteria solated in Japan to ceftazidime, ceftaroline, and aztreonam–avibactam combinations, J Infect Chemother 21:148–51 [CrossRef] [Google Scholar]
  • Walkty A, Adam H, Baxter M, et al (2014) In vitro activity of plazomicin against 5015 Gram-negative and Gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother 58:2554–2563 [CrossRef] [PubMed] [Google Scholar]
  • Bassetti M, Righi E (2014) Eravacycline for the treatment of intraabdominal infections. Expert Opin Investig Drugs 23:1575–1584 [CrossRef] [PubMed] [Google Scholar]
  • Mensa B, Howell GL, Scott R, et al (2014) Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58:5136–5145 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.